Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

BriaCell Reports Benchmark-Beating Patient Survival and Clinical Benefit in Advanced Metastatic Breast Cancer

Author: Benzinga Newsdesk | September 08, 2023 07:03am

BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW))))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announces the completion of patient enrollment in its Phase 2 clinical study and reports clinical data showing strong patient survival benefit and clinical benefit in advanced metastatic breast cancer patients.

Posted In: BCTX TSX:BCT


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

08/02/2024 Humana Inc. (HUM)
08/05/2024 Marinus Pharmaceuticals, Inc. (MRNS)

NEW CASE INVESTIGATION

Ooma Inc (OOMA) AnaptysBio Inc (ANAB)
CORE Finalist